Key result
Biomimetic MOF-Al@NVs rescue ischemic cardiomyocytes and attenuate inflammation to ameliorate post-reperfusion cardiac dysfunction.
Why the study?
Does a biomimetic stem cell membrane-camouflaged, allicin-loaded metal-organic framework nanoplatform (MOF-Al@NVs) reduce inflammation and ameliorate acute-phase cardiac dysfunction in preclinical models of myocardial ischemia/reperfusion injury?
Does a biomimetic stem cell membrane-camouflaged, allicin-loaded metal-organic framework nanoplatform (MOF-Al@NVs) reduce inflammation and ameliorate acute-phase cardiac dysfunction in preclinical models of myocardial ischemia/reperfusion injury?
Answers are grounded in this paper and cite their sources.
A biomimetic allicin-loaded metal-organic framework nanoplatform (MOF-Al@NVs) dually targets cardiomyocyte apoptosis and macrophage efferocytosis to attenuate early inflammatory injury and cardiac dysfunction in preclinical myocardial ischemia-reperfusion models.
Reperfusion strategies, the clinical standard for acute myocardial infarction, inevitably trigger severe myocardial ischemia/reperfusion (MI/R) injury. The acute phase of MI/R causes dual imbalance: excessive cardiomyocyte apoptosis and impaired macrophage phagocytosis. This pathological mechanism, the aberrant accumulation of apoptotic cells, triggers secondary necrosis, thereby serving as a critical driver of inflammatory storm and maladaptive cardiac remodeling. However, there is currently no targeted anti-inflammatory therapeutic strategy for this early pathological mechanism. To break these treatment limitations, we engineered a biomimetic stem cell membrane-camouflaged, allicin-loaded metal-organic framework nanoplatform (MOF-Al@NVs). Leveraging the nanovesicles' ischemic homing capability and the MOF's high drug-loading capacity and acidic degradation properties, this platform enables rapid, targeted delivery and release of allicin (which has anti-apoptotic and anti-inflammatory effects) within the ischemic myocardium. In vitro and in vivo investigations demonstrate that MOF-Al@NVs efficiently rescue dying cardiomyocytes by scavenging reactive oxygen species (ROS) bursts and blocking the mitochondrial apoptotic pathway. Concurrently, the platform re-orchestrates cardio-immune homeostasis by cooperatively upregulating the efferocytic receptor axis (TREM2/MERTK) on macrophages via activation of the PI3K/Akt signaling cascade. This dual coordinative effect accelerates the clearance of cellular debris and promotes the anti-inflammatory phenotypic transition from M1 to M2 macrophages, thereby attenuating the inflammatory storm, ameliorating acute-phase MI/R-induced cardiac dysfunction, and improving short-term prognosis. High-resolution spatial transcriptomics, integrated with multi-omics, confirms that MOF-Al@NVs effectively restore spatial immunometabolic homeostasis in the early infarct border zone. This biomimetic nanoplatform offers a promising strategy for targeted anti-inflammatory therapy in early MI/R injury.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied Myocardial ischemia/reperfusion (MI/R) injury. Biomimetic stem cell membrane-camouflaged, allicin-loaded metal-organic framework nanoplatform (MOF-Al@NVs) was evaluated on Cardiomyocyte apoptosis, macrophage efferocytosis (TREM2/MERTK axis), M1-to-M2 macrophage polarization, and acute-phase MI/R-induced cardiac dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: